Effect of Patient Factors on Portal Vein and Hepatic Contrast Enhancement at Computed Tomography Scan With Protocol Combining Fixed Injection Duration and Patients’ Body Weight Tailored Dose of Contrast Material

Hui Ye 1

1. Department of Medical Imaging, Sun Yat-Sen University Cancer Center, Guangzhou, CHN

Corresponding author: Hui Ye, yehui345@163.com

Abstract

Introduction

Fixed injection duration with patients’ body weight tailored dose of contrast material was recommended as the practical scan protocol in multiphasic contrast-enhanced abdominal computed tomography (CT). This study evaluated the effect of the demographic variables on portal vein and hepatic contrast enhancement in hepatic arterial phase (HAP), aiming to reduce the patient-to-patient variability and optimize the HAP images.

Methods

This retrospective analysis included 87 patients who underwent abdominal enhancement multiphase CT from April to June 2022. All the patients were examined using protocol combining fixed injection duration and patients’ body weight tailored dose of contrast material. Univariate and multivariate linear regression analyses were performed between all patient characteristics and the contrast-enhanced CT number of portal vein and hepatic parenchyma during HAP.

Results

Univariate linear regression analysis demonstrated statistically significant correlations between the CT number of hepatic parenchyma, and the body mass index (BMI), body surface area (BSA), and total body weight (TBW) (all P < 0.001) during HAP. However, multivariate linear regression analysis showed that the BMI or BMI and age were of independent predictive values (P < 0.001). Also, only the age was independently and negatively related to the CT number of portal vein enhancement during HAP (r = -0.240, P < 0.05) according to univariate linear regression analysis.

Conclusions

Univariate linear regression analysis revealed a significant inverse correlation between portal vein CT value and age. By multivariate linear regression analysis, only the BMI and age were significantly correlated with liver parenchymal enhancement, while gender, TBW, BSA, and HT were not.
scan triggering technique [11-14], but these applications were pilot studies, and their superiority needs to be verified.

Empirically fixed delay from contrast injection was still the main method of triple-phase helical CT in our daily examinations because of its relatively simple workflow and lower radiation dose. The use of fixed injection duration of patients’ body weight tailored dose of contrast material was recommended as ultimately optimal but practical injection/scan protocol by Ichikawa et al. [15]. According to them, the portal venous structures are moderately contrast-enhanced but hepatic veins are not contrast-enhanced in images of optimal scan timing of HAP. However, due to the impact of individual and contrast injection factors, it is difficult to grab these optimal scan timing HAP images, as sometimes the portal venous structures are not contrast-enhanced or sometimes hepatic veins are contrast-enhanced. In addition, the patient-to-patient variability of liver and vascular enhancement was obvious.

This retrospective study would be helpful in exploring a better multiphasic contrast-enhanced CT protocol of the liver. After finding the factors that have a significant impact on portal vein and hepatic parenchyma enhancement during HAP, this injection and scan protocol will probably be improved by adjusting the protocol according to these factors.

**Materials And Methods**

This retrospective analysis included 87 patients who underwent abdominal enhancement multiphase CT from April to June 2022 at our institute, excluding patients with incomplete records of height (HT) and weight, serious cirrhosis, and serious fatty liver, and patients after partial hepatectomy. Among the 87 patients, there were 45 men and 42 women, with an age range of 26 to 85 years (mean: 56.74 years) (Table 1). In these 87 patients, the clinical diagnoses were lung cancer (n = 49), nasopharyngeal carcinoma (n = 14), breast cancer (n = 3), colorectal cancer (n = 4), cervical cancer (n = 1), liver lesions (n = 2), esophageal cancer (n = 2), thyroid nodule (n = 1), oophorhagical carcinoma (n = 1), pancreatic cancer (n = 1), prostate cancer (n = 1), gastric cancer (n = 1), renal carcinoma (n = 1), ovarian cancer (n = 1), malignant peritoneal mesothelioma (n = 1), urachal anomalies (n = 1), neuroendocrine carcinoma (n = 1), and lung neoplasm (n = 2). Approval from the Institutional Review Board of Sun Yat-Sen University Cancer Center was obtained for this retrospective study on August 23, 2022 (approval number: B2022-427-01).

|          | Minimum | Maximum | Mean       |
|----------|---------|---------|------------|
| Age      | 26.00   | 85.00   | 56.74 ± 11.73 |
| TBW      | 34.00   | 96.00   | 58.42 ± 11.57 |
| HT       | 140.00  | 185.00  | 162.62 ± 8.36 |
| BSA      | 1.16    | 2.20    | 1.62 ± 0.19 |
| BMI      | 15.11   | 28.37   | 21.91 ± 2.95 |

**TABLE 1: Patient characteristics.**

TBW, total body weight; HT, height; BSA, body surface area; BMI, body mass index

Using a 128-detector CT scanner (Brilliance iCT; Philips Healthcare, Cleveland, Ohio), contrast-enhanced multidetector CT studies were performed with the patient in the supine position during a single breath-hold. We scanned craniocaudally from the top to the lower end of the liver. The CT scanning parameters were 0.5-second rotation scan, 128×0.625-mm collimation, 0.993 helical pitch, 158.9mm/second table speed, 120-kVp tube voltage, using Z-DOM dose modulation. The scanning time varied from 1.9 to 2.4 seconds.

We inserted a 22-gauge catheter into an antecubital (in most patients) or cubital vein and injected the contrast material with Iopamidol 370 (37g I/100mL) 1.2 mL/kg with a power injector (XD 8006, Ulrich Gmbh & Co.KG, Buchbrunnenweg, Germany) in 29-31 seconds. All the contrast media was warmed with body temperature (about 37 degrees C) before administration, reducing its viscosity and increasing the efficiency of delivering high-viscosity contrast media through small-bore catheters. A total of 30 mL of saline flush was injected at the same rate as the contrast material injection at the end of the duration.

All the patients underwent abdomen plain CT and contrast-enhanced CT including HAP, hepatic parenchymal phase (HPP), and equilibrium phase (EP). Scan start time after the beginning of injection of contrast material for each phase was 35 seconds for HAP, 65 seconds for HPP, and 3 minutes for EP.

In the liver, three small circular regions of interest (ROI) with an area of approximately 50mm² were selected.
respectively from the left, right anterior, and posterior hepatic lobes, being at a distance of about 1cm from the edge of the liver and avoiding blood vessels, focal hepatic lesions, bile ducts, calcifications, and artifacts. CT mean numbers of the three ROIs were calculated and recorded as liver parenchyma CT values. The CT numbers were also measured by an ROI within the main portal vein.

Patient’s gender, age, total body weight (TBW), HT, body mass index (BMI), and body surface area (BSA) were thought to be the factors of contrast enhancement in CT imaging according to previous articles [16-18]. The gender, age, TBW, and HT of the patients were recorded, and the BMI and BSA were calculated. Estimated BSA (in square meters) was calculated using the following equation: BSA = 0.007184 times \(H^{0.725} \times W^{0.425}\), where \(H\) is HT (in centimeters) and \(W\) is TBW (in kilograms) [19]. The BMI was defined as TBW (in kilograms) divided by the square of the HT (in meters).

Univariate and multivariate linear regression analyses were performed between all patient characteristics and the contrast-enhanced CT number of portal vein or hepatic parenchyma during HAP. Variables with p-values less than 0.05 were considered statistically significant. The Statistical Package for Social Sciences software (SPSS for Windows, Version 26.0, IBM Corp., Armonk, NY) was used for statistical computing.

### Results

As presented in Table 1, of the 87 patients, 45 were men and 42 were women. their age ranged from 26 to 85 years (mean: 56.74 ± 11.73 years), the TBW from 34.0 to 96.0 kg (mean: 58.4 ± 11.6 kg), HT from 140.0 to 185.0 cm (mean: 162.6 ± 8.4 cm), BSA from 1.2 to 2.2 m² (mean: 1.6 ± 0.2 m²), and BMI from 15.1 to 28.4 kg/m² (mean: 21.9 ± 3.0 kg/m²).

Among the 87 patients, there were no patients’ HAP images with contrast-enhanced hepatic veins, indicating the HAP scan timing, which was 35 seconds after the beginning of injection of contrast material, which cannot be considered as too late in daily clinical practice according to the visual confirmation of HAP scan timing suggested by Ichikawa et al. [15].

Univariate linear regression analysis only revealed a significant inverse correlation between portal vein CT value and age (\(r = 0.240, P < 0.05\)) (Table 2, Figure 1).

| Model | R    | R square | Durbin-Watson | F   | Sig.  |
|-------|------|----------|---------------|-----|-------|
| Age   | 0.240| 0.058    | 1.927         | 5.216| 0.025 |
| TBW   | 0.004| 0.000    | 1.967         | 0.001| 0.974 |
| HT    | 0.004| 0.000    | 1.965         | 0.001| 0.970 |
| BMI   | 0.014| 0.000    | 1.972         | 0.016| 0.898 |
| BSA   | 0.003| 0.000    | 1.966         | 0.001| 0.981 |

**TABLE 2: Effect of age, TBW, HT, BMI, and BSA on portal vein CT value during HAP.**

R, related coefficient; TBW, total body weight; HT, height; BMI, body mass index; BSA, body surface area; HAP, hepatic arterial phase; Sig., significant
According to Levene’s test for equality of variances and t-test for equality of means, the variance between the male and female groups of data is uniform and there was no significant difference in the portal vein CT value between men and women (109.59 ± 31.895 vs 121.76 ± 33.006 HU, P = 0.084) (Table 3, Figure 2).

FIGURE 1: Scattergrams of the relationship between portal vein CT value and the patient age. Unitary linear regression model: $y=108.411 - 1.415x$.

$y$, portal vein CT value; $x$, age; $R$, related coefficient

| Levene’s test for equality of variances | t     | df  | Sig. (two-tailed) | Mean difference |
|----------------------------------------|-------|-----|------------------|-----------------|
| Equal variances assumed                | 0.053 | 85.000 | 0.818            | -1.746          |
| Equal variances not assumed            | -1.748| 84.091 | 0.084            | -12.166         |
FIGURE 2: The box-and-whisker plot showing portal vein CT value for men and women.

Univariate linear regression analysis revealed a significant inverse correlation between liver parenchyma CT value, and the TBW ($r = 0.376$), BSA ($r = 0.317$), and BMI ($r = 0.442$), ($P < 0.01$ for all) (Table 4, Figures 3-5).

| Model | $R$  | $R$ square | Durbin-Watson | $F$   | Sig. |
|-------|------|------------|---------------|-------|------|
| Age   | 0.181| 0.033      | 1.361         | 2.882 | 0.093|
| TBW   | 0.376| 0.142      | 1.568         | 14.038| 0.000|
| BMI   | 0.442| 0.195      | 1.612         | 20.635| 0.000|
| BSA   | 0.317| 0.101      | 1.512         | 9.506 | 0.003|
| HT    | 0.141| 0.020      | 1.398         | 0.722 | 0.193|

TABLE 4: Effect of age, TBW, HT, BMI, and BSA on liver parenchyma CT value during HAP.

$R$, related coefficient; Sig., significant; TBW, total body weight; BMI, body mass index; BSA, body surface area; HT, height; HAP, hepatic arterial phase.
FIGURE 3: Scattergrams of the relationship between liver parenchyma CT value and TBW. Unitary linear regression model: \( y=108.411-1.415x \).

\( y \), liver parenchyma CT value; \( x \), total body weight; TBW, total body weight; \( R \), related coefficient

FIGURE 4: Scattergrams of the relationship between liver parenchyma CT value and BMI. Unitary linear regression model: \( y=108.411-1.415x \).

\( y \), liver parenchyma CT value; \( x \), body mass index; BMI, body mass index; \( R \), related coefficient
According to Levene’s test for equality of variances and t-test for equality of means, the variance between the male and female groups of data is uniform and there was a significant difference in the liver parenchyma CT value between men and women (75.21 ± 9.194 vs 79.75 ± 9.268 HU, $P = 0.024$) (Table 5, Figure 6).

**TABLE 5: Levene’s test for equality of variances and t-test for equality of means.**

df, degree of freedom; Sig., significance

---

**FIGURE 5: Scattergrams of the relationship between liver parenchyma CT value and BSA. Unitary linear regression model: $y=108.411-1.415x$.**

$y$, liver parenchyma CT value; $x$, body surface area; BSA, body surface area; $R$, related coefficient
However, multivariate linear regression analysis showed that only age and BMI were of independent predictive values for liver parenchyma CT value ($P < 0.01$) (Tables 6, 7).

### TABLE 6: Results of multivariate linear regression analysis of the enhancement of the liver parenchyma during HAP.

HAP, hepatic arterial phase; Sig., significant; VIF, variance inflation factor; BMI, body mass index; Std. error, standard error
TABLE 7: Excluded variables of multivariate linear regression analysis of the liver parenchyma CT value during HAP.

| Excluded variables | Model | Beta In | t   | Sig.    | Partial correlation | Collinearity statistics |
|--------------------|-------|---------|-----|---------|---------------------|-------------------------|
|                    |       |         |     |         |                     | Tolerance               |
|                    | 1     | Gender  | 0.138b | 1.383   | 0.170 | 0.149 | 0.936 |
|                    |       | Age     | -0.216b | -2.288  | 0.026 | -0.240 | 0.994 |
|                    |       | TBW     | 0.064b | 0.306   | 0.760 | 0.033 | 0.219 |
|                    |       | BSA     | 0.066b | 0.424   | 0.673 | 0.046 | 0.397 |
|                    |       | HT      | 0.046b | 0.431   | 0.668 | 0.047 | 0.835 |
|                    | 2     | Gender  | 0.139c | 1.428   | 0.157 | 0.155 | 0.936 |
|                    |       | TBW     | -0.025c | -0.121  | 0.904 | -0.013 | 0.211 |
|                    |       | BSA     | -0.005c | -0.034  | 0.973 | -0.004 | 0.380 |
|                    |       | HT      | -0.005c | -0.045  | 0.964 | -0.005 | 0.797 |

*Dependent variable: liver parenchyma CT value. *bPredictors in the model: constant, BMI. *cPredictors in the model: constant, BMI, and age.

"Beta In" values can be treated as possible "Beta" values but not correlation coefficient

Sig., significant; TBW, total body weight; HT, height; BMI, body mass index; BSA, body surface area; HAP, hepatic arterial phase

Discussion

According to previous studies, after using the protocol with contrast material dose determined according to patient weight, aortic peak time, aortic peak enhancement, and period when aortic enhancement is 200 HU were not related to the patients’ TBW [20], maximum aortic and hepatic parenchyma enhancement, time to maximum hepatic enhancement, and the end of HAP were not related to the injection rates [21]. Further research has shown that the peak enhancement times of aorta, main portal vein, and liver parenchyma were approximately 10, 20, and 30 seconds, respectively, after the completion of the injection respectively, regardless of patient weight and injection duration while the dose of contrast material is adjusted to patient weight [22]. However, HAP scanning may be sometimes performed too early or too late with this optimal injection protocol [15]. Since the impact of individual factors was not considered in these studies, analyzing individual factors may be one way to explore a duration providing more uniform scan timing and enhancement. The present research was a retrospective study aiming to evaluate the effect of age, gender, TBW, HT, BSA, and BMI on liver contrast enhancement with scan protocol combining fixed injection duration and patients’ body weight tailored dose of contrast material.

The present study suggests that by univariate linear regression analysis, HT, TBW, BSA, BMI, and gender did not exert a statistically significant effect on portal vein enhancement during the HAP, suggesting that the scan protocol can resolve the interindividual varying transit times of portal vein due to body size, which seemed in agreement with the findings of previous studies [15,20-22].

However, TBW (r = 0.376, P < 0.01), BSA (r = 0.317, P < 0.01), BMI (r = 0.442, P < 0.01) were all significantly related to contrast enhancement of hepatic parenchyma by univariate linear regression analysis, and there was significant difference in the liver parenchyma CT value between men and women. BMI and age have independent predictive values of hepatic parenchyma during the HAP by multivariate linear regression analysis. These results seem to stand in contrast to the results of Awai and Hori [21], who found that maximum aortic and hepatic enhancement was not related to the injection rates (which was perfectly linear correlated to TBW with fixed injection duration with patients’ body weight tailored dose of contrast material). However, in Awai et al.’s study, test injection of contrast material was used to determine start time of the scan, and the start time of the HAP was not recorded and analyzed. In the present study, the scan time started after 35 seconds from the start of the fixed duration for all patients. Therefore, the CT value of hepatic parenchyma was different because of the different rising rate of the CT value caused by the individual
Factors including TBW, BSA, BMI, gender, and age. It can be inferred from the result above that the start time of the HAP and peak enhancement time of hepatic parenchyma should be delayed in patients with higher TBW, BSA, or BMI, or with older age or being male to reduce the patient-to-patient variability of liver parenchyma.

Studies [23-24] suggest that the enhancement of vessels and parenchymal organs tended to be consistent and adequate regardless of patients’ body weight with BSA-tailored dose of contrast material. Fixed duration injection protocol was also used in these studies, but contrary to the current study, bolus tracking was used for the scanning delay. The object of Yanaga et al.’s study [23] was aorta and liver attenuation, whereas the current study focuses on portal vein and liver attenuation. In the study by Kidoh et al. [25], fixed duration tailed by TBW was used as well, and the correlation between the CT number per gram of iodine (Δ Hounsfield units/g) and TBW, BMI, BSA, and HT, during HAP were described as strong inverse correlation (r = 0.53, P < 0.001), moderate inverse correlation (r = 0.73, P < 0.001), strongest inverse correlation (r = 0.76, P < 0.001), moderate inverse correlation (r = 0.52, P < 0.001), respectively. Bolus tracking was used for the scanning delay as well, which maybe the reason for the difference with the present study. Since the BMI had the highest Pearson correlation R value with hepatic parenchyma CT value, the present study indicates that the contrast material adjusted by BMI may be a better way to reduce the patient-to-patient variability of parenchyma enhancement during HAP.

According to Bae’s report, patient body size (weight and HT) and cardiac output (CO) are the key patient-related factors affecting contrast enhancement. The relationship between portal vein or hepatic contrast enhancement and CO was not investigated in the present study. But since CO is perfectly linear correlated to BSA in this study according to the equations in Bae’s study: CO (mL/min) = 25.3 times (H)0.725 × (W)0.425 [16], where H is HT in centimeters and W is TBW in kilograms, the correlation inference can be drawn that there was no significant correlation between portal vein CT value and CO, and that there was a significant inverse correlation between liver parenchyma CT value and CO. This was in accord with the result of Masuda et al.’s study [26], which demonstrated a statistically significant inverse correlation between CO and aortic enhancement per gram of iodine by multivariate linear regression analysis.

In the present study, only the age (r = 0.240, P < 0.05) of the patient was significantly related to contrast enhancement of the portal vein during the HAP by univariate linear regression analysis. The result was in agreement with an earlier study by Sandstede et al. [9], who considered age as a positive factor of delayed contrast material arrival, which might explain the significant decrease in portal vein enhancement in the elderly.

In the present study, there was a significant difference in the liver parenchyma CT value between men and women. This may be caused by the less blood volume in female patients according to Bae’s study [16]. However, there was no significant difference in the portal vein CT value between men and women. This result indicated that the mesenteric blood volumes may be similar between males and females with the same TBW.

Apart from the visual confirmation of HAP scan timing suggested by Ichikawa et al. [15], there were different definitions of an optimal arterial phase. In the study of Sandstede et al., optimal arterial enhancement was defined as 20 ± 30% of hepatic enhancement in the portal venous phase [9]. An earlier study [27] defined optimal arterial phase start when a splenic parenchymal enhancement reach 10 HU, and the end was marked by any decrease of enhancement in the aorta or enhancement in the liver parenchyma of more than 20 HU. Therefore, the factors should be considered differently by different definitions of an optimal arterial phase according to the present study.

Some limitations of our study should be mentioned. First, the study was a retrospective single-center study, and thus more prospective studies are needed to confirm these results. Second, the BSA was calculated according to the DuBois formula. However, there are other formulae such as Mosteller, Gehan, and Haycock formulae, and the study did not compare the effect of BSA calculated by these formulae on the CT numbers in portal vein and hepatic parenchyma. Third, the change in CT number in the portal vein and the hepatic parenchyma from unenhanced images to the HAP images was not calculated. The relationship between patient characteristics and the change in the CT numbers in portal vein and hepatic parenchyma is worth pursuing in further study.

Conclusions

In conclusion, when hepatic CT was performed under the fixed injection duration with patients’ TBW-adjusted dose of contrast material, the age was the only independent factor with influence on portal vein enhancement during HAP by univariate linear regression logistic analysis. On multivariate linear regression logistic analysis, only BMI and age exhibited a significant correlation with liver parenchymal enhancement during HAP.

Additional Information
Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Institutional Review Board of Sun Yat-Sen University Cancer issued approval B2022-427-04. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Baron RL: Understanding and optimizing use of contrast material for CT of the liver. AJR Am J Roentgenol. 1994, 163:523-51. 10.2214/ajr.163.2.8057023
2. Mitsuzaki K, Yamashita Y, Ogata I, Nishihara T, Uraji T, Takahashi M: Multiple-phase helical CT of the liver for detecting small hepatomas in patients with liver cirrhosis: contrast-injection protocol and optimal timing. AJR Am J Roentgenol. 1996, 167:755-6. 10.2214/ajr.167.5.8756909
3. Honda Y, Higaki T, Higashihori H, Monzen Y, Tatsugami F, Date S, Akiw K: Re-evaluation of detectability of liver metastases by contrast-enhanced CT: added value of hepatic arterial phase imaging. Jpn J Radiol. 2014, 32:467-75. 10.1007/s11604-014-0351-z
4. Chiba A, Harada K, Ohashi Y, Nsumawaka K, Imaiz T, Hayasaka S: Evaluation of computed tomography arterial portography scan timing using different bolus tracking methods. Radiol Phys Technol. 2020, 13:92-7. 10.1007/s12194-020-00556-5
5. Sultana S, Akiw K, Nakayama Y, et al: Hypervascular hepatocellular carcinomas: bolus tracking with a 40-detector CT scanner to time arterial phase imaging. Radiology. 2007, 245:140-7. 10.1148/radiol.2451060069
6. Noda Y, Kawai N, Ishihara T, et al: Optimized scan delay for late hepatic arterial or pancreatic parenchymal phase in dynamic contrast-enhanced computed tomography with bolus-tracking method. Br J Radiol. 2021, 94:20210515. 10.1259/bjr.20210515
7. Kirkner J, Kickuth R, Laufer U, Noack M, Lieman K: Optimized enhancement in helical CT: experiences with a real-time bolus tracking system in 628 patients. Clin Radiol. 2000, 55:568-75. 10.1055/s-2000-3576
8. Mehner P, Pereira PL, Trubenhawj I, Kopp AF, Claussen CD: Biphasic spiral CT of the liver: automatic bolus tracking or time delay?. Eur Radiol. 2001, 11:427-31. 10.1007/s003300000635
9. Sandstedt JH, Tschammer A, Beer M, Vogelsang C, Wittenberg G, Hahn D: Optimization of automatic bolus tracking for timing of the arterial phase of helical liver CT. Eur Radiol. 2001, 11:1596-400. 10.1007/s0033000008816
10. Itoh S, Ikeda M, Achiwa M, Satake H, Iwano S, Ishigaki T: Late-arterial and portal-venous phase imaging of the liver with a multilbe CT scanner in patients without circulatory disturbances: automatic bolus tracking or empirical scan delay?. Eur Radiol. 2004, 14:1665-73. 10.1007/s00330-004-2352-1
11. Korparaa JG, Bishoff B, Arnold E, Sommer WH, Flohr TM, Schmidt B: Evaluation of a new bolus tracking-based algorithm for predicting a patient-specific time of arterial peak enhancement in computed tomography angiography. Invest Radiol. 2015, 50:531-8. 10.1097/RLI.0000000000000160
12. Gutfahr R, Fletcher JG, Lee YS, et al: Individualized delay for abdominal computed tomography angiography bolus-tracking based on sequential monitoring: increased aortic contrast permits decreased injection rate and lower iodine dose. J Comput Assist Tomogr. 2019, 43:612-8. 10.1097/RCT.0000000000001848
13. Yu J, Lin S, Lu H, Wang R, Liu J, Gutjahr R, Gao J: Optimize scan timing in abdominal multiphase CT: Bolus tracking with an individualized post-trigger delay. Eur J Radiol. 2022, 148:110139. 10.1016/j.ejrad.2021.110139
14. Bashir MR, Weber PW, Husarik DB, Howie LE, Nelson RC: Improved aortic enhancement in CT angiography using slope-based triggering with table speed optimization: a pilot study. Int J Cardiov Radiol. 2014, 28:1533-45. 10.1007/s10554-011-9945-8
15. Ichikawa T, Erturk SM, Araki T: Multiphasic contrast-enhanced multidetector-row CT of liver: contrast-enhancement theory and practical scan protocol with a combination of fixed injection duration and patients' body-weight-tailored dose of contrast material. Eur J Radiol. 2006, 58:165-76. 10.1016/j.ejrad.2005.11.057
16. Bae KT: Intravenous contrast medium administration and scan timing at CT: considerations at: Approaches. Radiology. 2010, 256:52-61. 10.1148/radiol.10090908
17. Bae KT, Seck BA, Hildebolt CF, Tao C, Zhu F, Kanematsu M, Woodard PK: Contrast enhancement in cardiovascular MDCT: effect of body weight, height, body surface area, body mass index, and obesity. AJR Am J Roentgenol. 2008, 190:777-84. 10.2214/AJR.07.2765
18. Itoh S, Ikeda M, Satake H, Ota T, Ishigaki T: The effect of patient age on contrast enhancement during CT of the pancreaticobiliary region. AJR Am J Roentgenol. 2006, 187:505-10. 10.2214/AJR.05.0541
19. Kouno T, Katsumata N, Mukai H, Ando M, Watanabe T: Standardization of the body surface area (BSA) formula to calculate the dose of anticancer agents in Japan. Jpn J Clin Oncol. 2005, 35:309-13. 10.1093/jjco/hyg062
20. Awai K, Hiraishi K, Hori S: Effect of contrast material injection duration and rate on aortic peak time and peak enhancement at dynamic CT involving injection protocol with dose tailored to patient weight. Radiology. 2004, 230:142-50. 10.1148/radiol.2301021080
21. Awai K, Hori S: Effect of contrast injection protocol with dose tailored to patient weight and fixed injection duration on aortic and hepatic enhancement at multidetector-row helical CT. Eur Radiol. 2005, 15:2155-60. 10.1007/s00330-005-1904-x
22. Erturk SM, Ichikawa T, Sou H, Tsukamoto T, Motosugi U, Araki T: Effect of duration of contrast material
injection on peak enhancement times and values of the aorta, main portal vein, and liver at dynamic MDCT with the dose of contrast medium tailored to patient weight. Clin Radiol. 2008, 63:263-71.

25. Yanaga Y, Asai K, Nakaura T, Utsunomiya D, Oda S, Hirai T, Yamashita Y: Contrast material injection protocol with the dose adjusted to the body surface area for MDCT aortography. AJR Am J Roentgenol. 2010, 194:905-8. 10.2214/AJR.09.5460

24. Kondo H, Kanematsu M, Goshima S, et al.: Body size indexes for optimizing iodine dose for aortic and hepatic enhancement at multidetector CT: comparison of total body weight, lean body weight, and blood volume. Radiology. 2010, 254:163-9. 10.1148/radiol.09090569

25. Kidoh M, Nakaura T, Oda S, et al.: Contrast enhancement during hepatic computed tomography: effect of total body weight, height, body mass index, blood volume, lean body weight, and body surface area. J Comput Assist Tomogr. 2013, 37:159-64. 10.1097/RCT.0b013e51827dcb08

26. Masuda T, Nakaura T, Funama Y, et al.: Aortic and hepatic contrast enhancement during hepatic-arterial and portal venous phase computed tomography scanning: multivariate linear regression analysis using age, sex, total body weight, height, and cardiac output. J Comput Assist Tomogr. 2017, 41:509-14. 10.1097/RCT.0000000000001513

27. Kopka L, Rodenwaldt J, Fischer U, Mueller DW, Oestmann JW, Grabbe E: Dual-phase helical CT of the liver: effects of bolus tracking and different volumes of contrast material. Radiology. 1996, 201:321-6. 10.1148/radiology.201.2.888218